| 2,817 | 20 | 73 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:基于网络药理学探讨柴胡达原饮治疗新型冠状病毒肺炎的分子机制。方法:通过TCMSP数据库收集柴胡达原饮的有效成分及靶点,按照OB值和DL值进行筛选,将所获得靶点蛋白名称输入Uniprot数据库将其转换成基因名,然后将得到的基因名导入Cytoscape v3.6.0构建网络,STRING数据库构建蛋白相互作用的网络图,最后采用DAVID数据库进行GO富集分析和KEGG富集分析,按P<0.05和FDR<0.05进行筛选,对"有效成分-靶点"拓扑分析所得度值较高的有效成分,进行分子对接。结果:采用Cytoscape软件对网络进行拓扑分析,其中节点度值前10的有效成分为槲皮素,靶点分别为PTGS2,AR,ESR1,PTGS1,PRSS1,NCOA2,PPARG,NOS2,ESR2。STRING数据库构建蛋白互作网络,网络中共包含230个节点,906条边,将网络信息数据导入Cytoscape软件进行拓扑分析可得出节点度值位于前十的靶基因,分别为STAT3,JUN,AKT1,MAPK1,MAPK3,APP,RELA,IL-6,CXCL8,MAPK14,表明上述靶点可能在疾病的治疗中发挥关键作用;使用DAVID数据库进行富集分析,对上述靶点所获得的230个基因进行分析,共得到30个富集的生物过程聚类,分为175个条目,最终得到30条;通路富集分析共获得29个富集的通路聚类,分为357条通路,最终得到通路57条;度值最高的有效成分槲皮素与ACE2受体进行分子对接,结果显示该成分与ACE2的结合能分布在-5 kcal/mol左右。结论:柴胡达原饮治疗新冠肺炎具有较好的理论基础,具有临床实践意义。
Abstract：Objective: To explore the feasibility of Chai Hu Da Yuan Decoction to treat COVID-19 based on network pharmacology. Methods: TCMSP database was used to collect the effective components and targets of Chai Hu Da Yuan Decoction, and OB value and DL value were used to screen the target protein, the name of which was input into UniProt database to convert it into gene name, and then the gene name was input into Cytoscape V3.6.0 to construct the network. STRING database was used to create the network diagram of protein interaction. David database was used for GO enrichment analysis and KEGG enrichment analysis. According to p<0.05 and FDR<0.05, the effective components with higher degree obtained from "effective component-target" topology analysis were screened for molecular docking. Results: The topological analysis of the network was carried out by Cytoscape. The top 10 effective components and targets were quercetin, PTGS2, AR, ESR1, PTGS1, PRSS1, NOCA2, PPARG, NOS2 and ESR2. The protein interaction network was established by STRING. The network consisted of 230 nodes and 906 sides. The network information was calculated according to the topological analysis by Cytoscape, then the top 10 target genes with node degree values were collected: STAT3, JUN, AKT1, MAPK1, MAPK3, APP, RELA, IL6, CXCL8 and MAPK14, which indicated that the above targets might play a key role in the treatment of diseases. David database was used for enrichment analysis and 230 genes were obtained from the above targets. The results showed 30 biological process clusters were enriched and 175 entries were obtained, finally 30 entries were collected. Passage enrichment analysis results showed 29 pathway clusters were enriched and 357 pathways were obtained, finally 57 pathways were obtained. The component with the highest degree— querceti was bound with ACE2 by molecular docking, the binding energy was about-5 kcal/mol. Conclusion: Chai hu Da Yuan Decoction has a good theoretical foundation for the treatment of COVID-19, which is important in clinical appliance.
[1]赵军宁,戴瑛,华桦,等.治疗新冠病毒肺炎(COVID-19)中药“药理谱-云”特点与有效性评价要素[J/OL].中药药理与临床,1-25[2020-03-24].https://doi.org/10.13412/j.cnki.zyyl.20200313.002.
[2]国家卫生健康委《新型冠状病毒肺炎诊疗方案(试行第七版)》.http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
[3]庄英杰,陈竹,李进,等.26例新型冠状病毒肺炎确诊病例临床和流行病学特征[J/OL].中华医院感染学杂志,1-4[2020-02-20].http://kns.cnki.net/kcms/detail/11.3456.R.20200219.1312.006.html.
[4]刘菊,崔瑛,白明学,等.基于中医药预防治疗新型冠状病毒肺炎的用药探析[J/OL].中草药,1-5[2020-02-20].http://kns.cnki.net/kcms/detail/12.1108.R.20200212.1133.002.html.
[5]韩园园,赵梦冉,石垚,等.中西医结合治疗新型冠状病毒肺炎的应用分析[J/OL].中草药,1-5[2020-02-20].http://kns.cnki.net/kcms/detail/12.1108.R.20200218.1652.010.html.
[6]王刚,金劲松.新型冠状病毒肺炎中医认识初探[J/OL].天津中医药,1-4[2020-02-20].http://kns.cnki.net/kcms/detail/12.1349.R.20200214.1710.004.html.
[7]刘清泉,夏文广,安长青,等.中西医结合治疗新型冠状病毒肺炎作用的思考[J/OL].中医杂志,1-2[2020-02-20].http://kns.cnki.net/kcms/detail/11.2166.R.20200215.1057.002.html.
[8]赵静,田赛赛,杨健,等.清肺排毒汤治疗新型冠状病毒肺炎机制的网络药理学探讨[J/OL].中草药,1-7[2020-02-20].http://kns.cnki.net/kcms/detail/12.1108.R.20200216.2044.002.html.
[9]徐旭,张莹,李新,等.各地区中医药预防新型冠状病毒(COVID-19)肺炎方案分析[J/OL].中草药,1-7[2020-02-20].http://kns.cnki.net/kcms/detail/12.1108.R.20200214.1506.002.html.
[10]王宪波,刘景院,王晓静,等.新型冠状病毒肺炎诊治实践与体会[J/OL].北京中医药,1-5[2020-02-20].http://kns.cnki.net/kcms/detail/11.5635.R.20200219.2120.004.html.
[11]仝小林,李修洋,赵林华,等.从“寒湿疫”角度探讨新型冠状病毒肺炎(COVID-19)的中医药防治策略[J/OL].中医杂志,1-6[2020-02-20].http://kns.cnki.net/kcms/detail/11.2166.R.20200217.2034.006.html.
[12]张维骏,刘润兰,张波.新型冠状病毒肺炎之五运六气解析[J/OL].中华中医药学刊:1-9[2020-02-20].http://kns.cnki.net/kcms/detail/21.1546.R.20200220.0806.002.html.
[13]郑榕,陈琴,黄铭涵.从“寒湿疫毒”辨治新型冠状病毒感染肺炎[J/OL].中国中医药信息杂志,1-3[2020-02-20].http://kns.cnki.net/kcms/detail/11.3519.r.20200213.1105.002.html.
[14]刘丁.新型冠状病毒肺炎疫情期间医院感染管理工作的思考[J/OL].重庆医学,1-7[2020-02-20].http://kns.cnki.net/kcms/detail/50.1097.r.20200220.1117.005.html.
[15]辛国,赵昕彤,黄晓巍.柴胡化学成分及药理作用研究进展[J].吉林中医药,2018,38(10):1196-1198.
[16]龚斌,李琴,胡小红,等.枳壳化学成分及药理作用研究进展[J].南方林业科学,2019,47(3):40-45.
[17]盛永成,王晶,张世洋,等.厚朴药理研究进展[J].成都中医药大学学报,2018,41(2):109-114.
[18]姜静岩,苗桂玲.青皮的药理及临床应用[J].时珍国医国药,2003,(6):374-375.
[19]李冀,李想,曹明明,等.甘草药理作用及药对配伍比例研究进展[J].上海中医药杂志,2019,53(7):83-87.
[20]果秋婷,张小飞.关于黄芩的化学成分与药理作用研究进展[J].科学技术创新,2019,(27):45-46.
[21]左军,尹柏坤,胡晓阳.桔梗化学成分及现代药理研究进展[J].辽宁中医药大学学报,2019,21(1):113-116.
[22]代敏,彭成.草果的化学成分及其药理作用研究进展[J].中药与临床,2011,2(4):55-59.
[23]易攀,汤嫣然,周芳,等.槟榔的化学成分和药理活性研究进展[J].中草药,2019,50(10):2498-2504.
[24]郭春延,张楠,薛晶晶,等.荷叶蜡质层处理与荷梗品质及抗氧化性[J].河北大学学报(自然科学版),2019,39(1):106-112.
[25].王训翠,储明星,陈宏权.前列腺素内过氧化物合酶2基因的研究进展[J].生命科学,2004,(1):31-34.
[26] 殷玲,周京国.雄激素及其受体在痛风炎症反应中作用[J].中华临床医师杂志(电子版),2013,7(13):6018-6020.
[27]吴宗林,袁亚,耿和,等.免疫性炎症与前列腺体积及雄激素受体表达的关系[J].现代生物医学进展,2011,11(16):3059-3062.
[28]杜海霞,周惠芬,何昱,等.银花平感颗粒和三拗汤体内抗甲型流感病毒的免疫机制研究[J].中国中药杂志,2018,43(5):1028-1033.
[29]姚草原,罗华.红景天苷对急性呼吸窘迫综合征大鼠肺损伤保护作用[J/OL].中国临床药理学杂志,1-4[2020-03-25].http://kns.cnki.net/kcms/detail/11.2220.R.20200217.1234.082.html.
[30]Tze Jen Chow,Shiau Foon Tee,Siew Yim Loh,et al.Analysis of variants of AKT1 in schizophrenia multiplex families[J].Asian Journal of Psychiatry,2020,49.
[31]孙鸽,夏献民.RelA翻译后修饰对核因子κB活性的调控作用[J].临床与病理杂志,2018,38(4):843-852.
[32]马欢欢.共振光散射光谱法测定几种抗病毒和抗炎药物分子[D].湘潭大学,2011.
[33]唐子健,李树仁,许文华,等.从2019-nCoV和SARS-CoV的侵袭靶点血管紧张素转化酶2寻找新型冠状病毒肺炎的救治策略[J].中国全科医学,2020,23(9):1071-1077.
基本信息:
DOI：10.13412/j.cnki.zyyl.20200409.001
中图分类号:R259
引用信息:
[1]刘改霞,张涛.基于网络药理学和分子对接技术探讨柴胡达原饮治疗新型冠状病毒肺炎的可行性[J].中药药理与临床,2020,36(02):102-108.DOI:10.13412/j.cnki.zyyl.20200409.001.
基金信息:
西安市科技局(编号:201805103YX11SF37)
2020-04-10
2020-04-10
2020-04-10